Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published June 1, 2018 | Accepted Version + Supplemental Material
Journal Article Open

Evolution of a Strategy for the Enantioselective Total Synthesis of (+)-Psiguadial B

Abstract

(+)-Psiguadial B is a diformyl phloroglucinol meroterpenoid that exhibits antiproliferative activity against the HepG2 human hepatoma cancer cell line. This full account details the evolution of a strategy that culminated in the first enantioselective total synthesis of (+)-psiguadial B. A key feature of the synthesis is the construction of the trans-cyclobutane motif by a Wolff rearrangement with in situ catalytic, asymmetric trapping of the ketene. An investigation of the substrate scope of this method to prepare enantioenriched 8-aminoquinolinamides is disclosed. Three routes toward (+)-psiguadial B were evaluated that featured the following key steps: (1) an ortho-quinone methide hetero-Diels–Alder cycloaddition to prepare the chroman framework, (2) a Prins cyclization to form the bridging bicyclo[4.3.1]decane system, and (3) a modified Norrish–Yang cyclization to generate the chroman. Ultimately, the successful strategy employed a ring-closing metathesis to form the seven-membered ring and an intramolecular O-arylation reaction to complete the polycyclic framework of the natural product.

Additional Information

© 2018 American Chemical Society. Received: March 22, 2018; Published: May 4, 2018. Prof. Greg Fu is gratefully acknowledged for insightful discussions. We thank Dr. Allen Oliver, Dr. Nathan Schley, and Ms. Julie Hofstra for X-ray crystallographic structure determination and Dr. David VanderVelde for assistance with NMR structure determination. We thank Dr. Scott Virgil and the Caltech Center for Catalysis and Chemical Synthesis for access to analytical equipment and Materia, Inc. for a donation of HG-II catalyst. Fellowship support was provided by the NSF (L.M.C. and C.R.L., Grant No. DGE-1144469), NIH Training Grant (J.C.B., Grant No. 5T32GM007616-39) and SNF (L.W., Grant No. PBZHP2-147311). S.E.R. is an American Cancer Society Research Scholar and a Heritage Medical Research Foundation Investigator. Financial support from the NSF (CAREER-1057143), the American Cancer Society, the Research Corporation Cottrell Scholars program, and DuPont is gratefully acknowledged. The authors declare no competing financial interest.

Attached Files

Accepted Version - nihms969614.pdf

Supplemental Material - jo8b00728_si_001.pdf

Supplemental Material - jo8b00728_si_002.cif

Files

nihms969614.pdf
Files (15.0 MB)
Name Size Download all
md5:f6b25a115654d6ab12ac40279bde67ff
1.5 MB Preview Download
md5:a49eb3cd2d52d704ab09054e54b3be37
12.8 MB Preview Download
md5:f560e00c3d3e925c36c2de939acd048c
765.6 kB Download

Additional details

Created:
August 19, 2023
Modified:
October 18, 2023